Neuphoria Therapeutics Inc.
- NEUP
- NASDAQ
- Biotechnology
- Neuropsychiatric Drug Development
- Clinical-Stage Biotech
$3.31
Today +0.30%Quote Oct 19, 2026, 08:00 PM UTC
−10.54%over the last month
Max drawdown −13.3%From 1-month high −11.4%3 months −0.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
1
Market value
$17.9M
Quote Oct 19
Analyst target
$7.00
+111.5% from here
Floor
$3.26
1.6% below price
Resistance
$3.34
1.0% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NEUPPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free